Sort
21,281 grants matching “influenza”
Surveillance and Response to Avian and Pandemic Influenza
$200,000Guillaume Louis Kiyombo Mbela · Kinshasa School Of Public Health · U51 · FY2006 · CI
Therapeutic efficacy of favipiravir against henipavirus infections
$200,000Alexander Niclas Freiberg · University Of Texas Med Br Galveston · R21 · FY2022 · AI
Social Network-Enabled Flu Trends (SNEFT)Integrating Online Social Network Data
$200,000Lingji Chen · Scientific Systems Company, Inc. · R43 · FY2010 · LM
Support Surveillance and Response to Avian and Pandemic Influenza
$200,000Abdulsalami Nasidi · Federal Ministry Of Health Nigeria · U51 · FY2007 · CI
Natural helper cells in allergic airway inflammation
$200,000Avinash Bhandoola · University Of Pennsylvania · R21 · FY2012 · AI
SWINE INFLUENZA VIRUSES CAUSE ACUTE RESPIRATORY INFECTION IN SWINE HERDS AND SIGNIFICANT ECONOMIC AND ANIMAL LOSSES TO THE SWINE INDUSTRY. IN THE UNITED STATES ALONE, THE PORK INDUSTRY LOST AN ESTIMATED $5 BILLION DUE TO THE 2009 H1N1 SWINE FLU OUTBREAK. SWINE CAN BE INFECTED WITH FOUR DIFFERENT INFLUENZA TYPES THAT VARY IN THE SEVERITY OF INFECTION. OF THE FOUR INFLUENZA VIRUSES, INFLUENZA A IS THE MOST PREVALENT, AND CAUSES THE HIGHEST MORBIDITY AND MORTALITY IN SWINE. EFFECTIVE VACCINES AGAINST INFLUENZA VIRUSES HAVE BEEN DEVELOPED AND ARE CURRENTLY THE BEST PREVENTATIVE TREATMENT OPTION AVAILABLE. HOWEVER, THESE VACCINES ARE NOT EFFECTIVE IN TREATING ALREADY INFECTED ANIMALS. IN ADDITION, NEW SWINE INFLUENZA VARIANTS ARISE THAT ARE NOT TARGETED BY VACCINES, AND THESE VIRUSES PERIODICALLY SPILL-OVER TO OTHER HOSTS INCLUDING HUMANS.INFLUENZA VIRUSES CANNOT REPLICATE ON THEIR OWN AND TAKE ADVANTAGE OF SWINE PROTEINS TO INFECT, REPLICATE, AND SPREAD TO OTHER CELLS. AS SUCH, INFLUENZA VIRUSES ARE ABSOLUTELY DEPENDENT ON HOST CELLS TO PROPAGATE AND SPREAD. TO LIMIT VIRAL REPLICATION AND SPREAD, SWINE CELLS USE A LIMITED DEFENSE SYSTEM AGAINST VIRAL PATHOGENS SUCH AS INFLUENZA. SWINE CELLS EXPRESS PROTEINS THAT LIMIT OR CREATE UNFAVORABLE CONDITIONS FOR VIRAL REPLICATION. NEW ANTI-INFLUENZA THERAPEUTIC STRATEGIES COULD POTENTIALLY BE DEVELOPED IF WE IDENTIFY ALL INFLUENZA DEPENDENCY FACTORS OR SWINE DEFENSE PROTEINS.TOWARDS THIS GOAL, WE WILL USE EMERGING GENE-EDIT TECHNOLOGIES TO DELETE EVERY SWINE GENE IN POOLS OF CELLS, WHERE ONE CELL HAS EXACTLY ONE DELETED GENE AND THE NEIGHBORING CELL HAS A DIFFERENT DELETED GENE. POOLS OF GENE-EDITED CELLS WILL BE INFECTED WITH A FLUORESCENT INFLUENZA VIRUS TO VISUALIZE INFLUENZA INFECTION IN CELLS. SWINE CELLS MISSING PROTEINS REQUIRED FOR INFLUENZA REPLICATION ARE EXPECTED TO PRODUCE LOW TO UNDETECTABLE INFLUENZA VIRUS LEVELS AS JUDGED BY LOW TO NO FLUORESCENCE. ON THE OTHER HAND, SWINE CELLS MISSING PROTEINS THAT FUNCTION TOLIMIT VIRAL REPLICATION ARE EXPECTED TO HAVE HIGH LEVELS OF INFLUENZA VIRUS AS JUDGED BY HIGHER FLUORESCENCE WHEN COMPARED TO NORMAL UNEDITED SWINE CELLS. NEXT-GENERATION DNA SEQUENCING METHODS WILL BE USED TO IDENTIFY DELETED GENES IN LOW AND HIGH FLUORESCENT CELLS, AND THE TOP GENES IDENTIFIED WILL BE VALIDATED AND SUBSEQUENTLY CHARACTERIZED. THIS STUDY WILL NOT REQUIRE THE USE OF LIVE ANIMALS AND WILL INSTEAD UTILIZE CELLS DERIVED FROM RESPIRATORY TISSUES SUCH AS SWINE TRACHEA AND LUNGS.OUR APPROACH IS UNCONVENTIONAL IN THAT WE WILL TARGET THE HOST CELLS RATHER THAN THE VIRUS ITSELF. WHILE INFLUENZA VIRUSES HAVE THE ABILITY TO CAUSE ILLNESS, THEY ALSO HAVE A CRITICAL WEAKNESS - THEY ARE UNABLE TO REPRODUCE ON THEIR OWN AND DEPEND ON THE PROTEIN-MAKING MACHINERY OF THEIR HOST TO PROPAGATE. THIS WEAKNESS IS WHAT WE ENVISION EXPLOITING AS AN ALTERNATIVE APPROACH TO COMBAT INFLUENZA VIRUS. THIS STUDY WILL CREATE NEW KNOWLEDGE AND TOOLS TO FACILITATE THE DEVELOPMENT OF NEW ANTI-INFLUENZA THERAPEUTICS THAT MIGHT FUNCTION TO BLOCK PROTEINS REQUIRED BY INFLUENZA VIRUSES AND/OR ACTIVATE SWINE ANTI-VIRAL DEFENSE SYSTEMS.
$200,000South Dakota State University · · FY2021 · National Institute of Food and Agriculture
ENHANCING THE INFLUENZA SURVEILLANCE AND CONTROL
$200,000Cojocaru Radu · Ministry Of Health · U51 · FY2015 · IP
MECHANISMS REGULATING AVIAN INFLUENZA VIRUS INFECTIONS IN HUMANS
$200,000Richard John Webby · St. Jude Children'S Research Hospital · R01 · FY2017 · AI
Sustaining Influenza Surveillance Networks and Response to Seasonal
$200,000Maria Eugenia Jimenez-Corona · Fundacion Mexico Estados Unidos/Cienca · U51 · FY2015 · IP
Mechanisms of Influenza a Virus Transmission in Ferretts
$200,000Daniel R Perez · Univ Of Maryland, College Park · U01 · FY2006 · CI
Delivery of Adolescent Preventive Services in the Era of New Adolescent Vaccines
$200,000Cynthia M Rand · University Of Rochester · U01 · FY2007 · IP
Delivery of Adolescent Preventive Services in the Era of New Adolescent Vaccines
$200,000Cynthia M Rand · University Of Rochester · U01 · FY2008 · IP
RAPID: Measuring host competence across wild bird species during outbreaks of highly pathogenic avian influenza
$199,999Nichola Hill · University Of Massachusetts Boston · · FY2022 · BIO
PiiiTCH Study
$199,996Emmanuel B Walter · Duke University · U01 · FY2007 · IP
RAPID: Antimicrobial Coatings for the mitigation of virus transmission on high-touch surface
$199,954Stephen J McDonnell · University Of Virginia Main Campus · · FY2020 · MPS
EVALUATING USE A RAPID TESTING FOR INFLUENZA IN OUTPATIENT MEDICA SETTING
$199,945Nancy Jean Kupka · Joint Commission · U47 · FY2007 · CI
Innate and adaptive immune responses at the respiratory mucosa
$199,914Yasmin Thanavala · Roswell Park Cancer Institute Corp · R21 · FY2009 · AI
Ultra-low dose Influenza vaccines
$199,904Steffen Mueller · Codagenix, Inc. · R43 · FY2015 · AI
Ultra-low dose Influenza vaccines
$199,904Steffen Mueller · Codagenix, Inc. · R43 · FY2014 · AI
PiiiTCH Study
$199,896Emmanuel B Walter · Duke University · U01 · FY2006 · IP
Aging, T cell repertoire, and cellular immunity to influenza virus
$199,875Marcia A Blackman · Trudeau Institute, Inc. · R01 · FY2014 · AG
Development of MMP14-laden exosomes as a novel anti-SARS-CoV-2 therapy
$199,875Kyuyeon Han · University Of Illinois At Chicago · R21 · FY2023 · AI
A Sensitive and Serotype-Specific Dengue Diagnostic Test for Low-Resource Setting
$199,859Season S-S Wong · Ai Biosciences, Inc. · R43 · FY2014 · AI
Distinct Function and Control of Regulatory T Cell Subsets During Influenza
$199,840Jason W. Griffith · Massachusetts General Hospital · K08 · FY2019 · AI
Distinct Function and Control of Regulatory T Cell Subsets During Influenza
$199,840Jason W. Griffith · Massachusetts General Hospital · K08 · FY2020 · AI